Nebenwirkungen · Tagrisso
TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 14
HOS-135445 · Präparat HOS-097706
Patients receiving TAGRISSO monotherapy (80 mg; N=1956) with low body weight (<50 kg) reported higher frequencies of Grade ≥3 adverse reactions (20% versus 10%) and QTc prolongation (12% versus 6%) than patients with higher body weight (≥50 kg). Patients who received TAGRISSO in combination with pemetrexed and platinum-based chemotherapy with low body weight (<50 kg) reported similar frequencies of Grade ≥3 adverse reactions (32% versus 37%) when compared to patients with higher body weight (≥50 kg). In contrast, dry skin (34% versus 22%) and stomatitis (40% versus 30%) were reported at higher frequencies in patients with low body weight (<50 kg) versus higher body weight (≥50 kg).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T16:00:00Z · SHA-256 36d1f10f3b323cac93ed4124915e050ad98541d8f140829a41c0c4e0ad3343cb · Passage 56d2a2652953f9a18f70937bcd03fc03037c9b4c51f26b6c2d85bd1bf6d52fa0 · Zeichen 17868–18558 im Abschnitt